Categories: Market Research

Global Lewy Body Dementia Treatment Market Size and Forecast 2024-2033| Mallinckrodt Pharmaceuticals Co., BioArctic AB, Sumitomo Pharma Co. Ltd., Jazz Pharmaceuticals Inc., Allergan PLC

A real life, real person senior adult woman home caregiver daughter is about to push her elderly 89 year old mother in her wheelchair down their home's front walkway ramp for fresh air and outdoor scenery. Mother has dementia with lewy bodies; a difficult illness and overall situation for her daughter to care for and personally deal with. So a nice walk outside is good for the younger woman's well-being as well.

The Lewy Body Dementia Treatment by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Lewy Body Dementia Treatment Market

https://www.thebusinessresearchcompany.com/report/lewy-body-dementia-treatment-global-market-report

According to The Business Research Company’s Lewy Body Dementia Treatment, The lewy body dementia treatment market size has grown strongly in recent years. It will grow from $4.14 billion in 2023 to $4.41 billion in 2024 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to supportive care and family education, regulatory approvals and guideline, multidisciplinary care approaches, psychosocial and behavioral interventions, multidisciplinary care approaches.

The lewy body dementia treatment market size is expected to see strong growth in the next few years. It will grow to $5.68 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to advancements in neurology, focused research initiatives, precision medicine and biomarkers, collaborative healthcare models, telemedicine expansion.. Major trends in the forecast period include family and caregiver support, integrated care models, personalized treatment approaches, non-pharmacological interventions, digital health solutions.

The rising prevalence of brain-related disorders is expected to propel the growth of the lewy body dementia treatment market going forward. Brain disorders refer to any disorder that impairs brain function. The impairment can be mild, moderate, or severe, depending on the extent of brain damage. Lewy body dementia treatment is used to treat brain disorders such as hallucinations, confusion, and drowsiness by increasing brain chemicals to improve alertness and cognition. For instance, in January 2022, according to a report shared by the American Heart Association Inc., a US-based nonprofit voluntary organization, brain disorders are expected to increase to 9.3 million in the US by 2060, and currently, this number is growing in the US. And one in every six people worldwide suffers from a brain disease. Currently, 1 billion people will suffer from brain disorders worldwide by 2021. Therefore, the rising prevalence of brain-related disorders is driving the growth of the lewy body dementia treatment market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=9387&type=smp

The lewy body dementia treatment market covered in this report is segmented –

1) By Drug Type: Antidepressants, Antipsychotic Drugs, Benzodiazepine, Carbidopa-Levodopa, Cholinesterase inhibitors, Modafinil

2) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

3) By Application: Alzheimer’s disease, Dementia, Parkinson’s disease

Product innovation is a key trend gaining popularity in the lewy body dementia treatment market. Major companies operating in lewy body dementia treatment are focused on developing innovative solutions to strengthen their position in the market. For instance, in January 2023, Biogen Inc., a US-based multinational biotechnology company, developed its new medicine, lecanemab, which is a humanised monoclonal antibody. This medicine is used to treat Alzheimer’s disease, which is part of the disease in Lewy body dementia. The main unique benefit of lecanemab is that it reduces the levels of brain amyloid. It treats the brain and clears the amyloid plaques thought to cause cognitive impairment and dementia in Alzheimer’s disease.

The lewy body dementia treatment market report table of contents includes

1. Executive Summary

2. Lewy Body Dementia Treatment Market Characteristics

3. Lewy Body Dementia Treatment Market Trends And Strategies

4. Lewy Body Dementia Treatment Market – Macro Economic Scenario

5. Global Lewy Body Dementia Treatment Market Size and Growth

26. South America Lewy Body Dementia Treatment Market

27. Brazil Lewy Body Dementia Treatment Market

28. Middle East Lewy Body Dementia Treatment Market

29. Africa Lewy Body Dementia Treatment Market

30. Lewy Body Dementia Treatment Market Competitive Landscape And Company Profiles

Top Major Players: